Clinical trials: Essential Hypertension.
Hypertension, Isolated Systolic Hypertension (ISH)
A Single Rising Dose Study of MK-8150 (MK-8150-001)
This study will evaluate the safety and tolerability of MK-8150 and its effect on central systolic blood pressure (cSBP) and heart rate corrected augmentation index (AIx) when given as single oral doses in healthy males and in…
- Trial name
- NCT01590810
- Testing
- MK-8150 2.0 mg, MK-8150 10 mg, MK-8150 40 mg
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Primary Hypertension
The Effectiveness of "MaRiTensi" in Increasing Self-Care and Blood Pressure Control: Randomized Controlled Trial
This study aims to know the effectiveness of "MaRiTensi" in improving knowledge, motivation, efficacy, self-care and blood pressure control for hypertension patients.
- Trial name
- "MaRiTensi" (NCT06049862)
- Testing
- MaRiTensi App
- Where
- 3 sites in Indonesia
- Volunteers
- 99 people
- Sponsor
- Chatarina Setya Widyastuti
Primary Hypertension
The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble
The investigators intend to find a noninvasive method for CB modulation therapy and find a simple and convenient indicator for assessing CB activity.
- Trial name
- NCT06116357
- Testing
- External Ultrasonic Micro-bubble
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Jing Huang
Hypertension
Physical Exercise in Hypertension, Randomised Clinical Trial
Endurance training has a documented effect on hypertension. However, only low to moderate training intensity has so far been studied.
- Trial name
- NCT00218972
- Testing
- Aerobic interval training, moderate intensity training, Recommendation of regular exercise
- Where
- Norway
- Volunteers
- 88 people
- Sponsor
- Norwegian University of Science and Technology
Hypertension
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.
- Trial name
- NCT01415531
- Testing
- Nebivolol
- Where
- 75 sites in United States
- Volunteers
- 641 people
- Sponsor
- Forest Laboratories
Hypertension
Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient
To investigate the safety and efficacy of the long-term use of amlodipine 10 mg in subjects who will be able to enter a long-term study after completing the parent study "A double-blind comparative study between amlodipine 5 mg…
- Trial name
- NCT00443456
- Testing
- Amlodipine
- Where
- 9 sites in Japan
- Volunteers
- 134 people
- Sponsor
- Pfizer
Essential Hypertension
A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers
The purpose of this study is to evaluate the effect of fimasartan on pharmacokinetics, and the safety of digoxin.
- Trial name
- NCT00991783
- Testing
- Digoxin + Fimasartan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension,Essential, Lifestyle-related Condition
The Föllinge Hypertension and Lifestyle Study
Ambulatory blood pressure measurement is more demanding in terms of technical equipment and specially trained staff. If blood pressure measurement in a self-care room is on average equivalent to the ambulatory blood pressure…
- Trial name
- FIHST (NCT04488289)
- Testing
- Lifestyle
- Where
- Sweden
- Volunteers
- 117 people
- Sponsor
- Umeå University
Hypertension, Hypertension,Essential
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
- Trial name
- NCT06205628
- Testing
- ADX-850
- Where
- 3 sites in Australia
- Volunteers
- 28 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
Hypertension,Essential, Obesity
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects
The reducing the anti-aggregation properties of platelets significantly decreases the risk of myocardial infarction and the total number of cardiovascular events.
- Trial name
- NCT03206944
- Testing
- acetylsalicylic acid, Tomato Fruit Extract
- Volunteers
- 82 people
- Sponsor
- Beata Krasinska
Essential Hypertension
Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study
Background: The use of thiazide diuretics in the treatment of hypertension (HT) is widely considered a first line treatment, given the efficacy and low cost of this class of drugs.
- Trial name
- stayondiur (NCT00408512)
- Testing
- thiazides, Non thiazidic treatment
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- Federico II University
Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02483936
- Testing
- Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg, Olmesartan 40mg + Hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Essential Hypertension
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CoCa (NCT00608153)
- Volunteers
- 1,773 people
- Sponsor
- AstraZeneca
Essential Hypertension
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential…
- Trial name
- NCT06671392
- Testing
- DWC202405, DWC202405, DWC202314, DWC202405, DWC202314P
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Primary Hypertension, Obesity
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.
Despite the available means of treating primary arterial hypertension, the prevalence of hypertensive patients with inadequately controlled blood pressure levels, remains high.
- Trial name
- NCT06208072
- Testing
- Irbesartan 150mg, Eplerenone 25 mg
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Hippocration General Hospital
Hypertension, Insulin Resistance
Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the insulin-induced microvascular dilatation. Objectives: 1.
- Conditions
- Hypertension, Insulin Resistance, Microcirculation
- Trial name
- NCT00742066
- Testing
- Irbesartan, Felodipine
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 compared to RLD2001-1 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT06438172)
- Testing
- HCP1803-3, RLD2001-1, HPP2003-3
- Where
- South Korea
- Volunteers
- 249 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
This is a national multicenter, prospective, observational study. It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment…
- Trial name
- NCT05947448
- Testing
- Azilsartan Medoxomil Potassium Tablet, Nifedipine Sustained -release Tablets, Levoamlodipine Maleate Table
- Where
- China
- Volunteers
- 1,215 people
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
Hypertension,Essential, Hypertension, Uncontrolled
Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System
The CHARGE-APP project will investigate whether an innovative management strategy of hypertension based on the combination of usual care visits and ESH CARE App compared to standard care, is associated with differences in…
- Trial name
- CHARGE-APP (NCT03206814)
- Testing
- Usual care, POST-strategy
- Where
- 8 sites in Argentina, China
- Volunteers
- 480 people
- Sponsor
- Istituto Auxologico Italiano
Hypertension
Effect of Intensive FMT on Primary Hypertension
Mounting preclinical and clinical evidences have proved the causal role of gut microbiota on the pathogenesis of primary hypertension.
- Trial name
- NCT05608447
- Testing
- FMT capsules
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital